News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Xillix Technologies (CT:XLX) Supports November Lung Cancer Awareness Month



11/9/2005 6:06:15 PM

Xillix Technologies Corp. (TSX:XLX), the world leader in fluorescence endoscopy for the early detection of cancer, today announced some of its recent activities in support of November's Lung Cancer Awareness Month. Lung cancer is the leading cause of cancer death in both men and women with a poor 15% five-year survival rate. The U.S. Food and Drug Administration (FDA) recently approved the Company's latest device, Onco-LIFETM for use in the detection of lung cancer. FDA approval of Onco-LIFE followed an international multi-center clinical trial which demonstrated that Onco-LIFE improved the detection of subtle early stage lung cancer (carcinoma in situ or Stage 0) and precancerous lesions (moderate-severe dysplasia) by 325% compared to conventional white-light endscopy alone.

Read at CCNMatthews


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES